



NORTHWEST BIOTHERAPEUTICS

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Avenue
Seventh Floor, Suite 750
Bethesda, MD 20814

www.nwbio.com
OTCBB: NWBT

(“NWBT”, “Northwest” or the “Company”)

NORTHWEST BIOTHERAPEUTICS HOLDS ANNUAL GENERAL MEETING

BETHESDA, MD –September 4, 2009 – Northwest Biotherapeutics, Inc. (AIM: NWBT and NWBS; OTCBB: NWBO) today announces that all resolutions put to the Company’s shareholders at today’s Annual General Meeting held today in Bethesda, MD, USA have been approved. The resolutions included: (1) the approval of Linda F. Powers as a Class Two Director; (2) the increase in the number of authorized shares in the Company from 100,000,000 to 150,000,000; and (3) the cancellation of the Company’s listing on the London Stock Exchange’s AIM market (“AIM”). The Company plans to continue its listing in the U.S., on the NASD Over the Counter Bulletin Board Market (“U.S. listing”) and plans to file an S1 registration statement under which the Company’s shares held on AIM may become tradable on the US market. The trading of the Company’s shares on AIM is expected to be cancelled on September 14, 2009.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 clinical sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax[®] for recurrent metastatic ovarian cancer. The Company’s second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission (“SEC”), future treatment of patients with GBM using DCVax[®]-



NORTHWEST BIOTHERAPEUTICS

Northwest
Biotherapeutics, Inc.

7600 Wisconsin Avenue
Seventh Floor, Suite 750
Bethesda, MD 20814

www.nwbio.com
OTCBB: NWBT

Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “expects,” “believes,” “intends,” “anticipates,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the SEC’s review and evaluation of securities registrations or other filings, the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties related to the clinical trials process, uncertainties about the timely performance of third parties, and uncertainties about whether the Company’s products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company’s results, is included in its SEC filings and the Risk Factors section of the Form S-1 that the Company is preparing to file. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings or upcoming Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

For further information, please contact:

Northwest Biotherapeutics, Inc.

Alton L. Boynton, Chief Executive Officer

+1 240 497 9024

Buchanan Communications

Lisa Baderon (lisab@buchanan.uk.com) / Mary-Jane Johnson /
Catherine Breen

+44 (0)20 7466 5000

Collins Stewart Europe Limited

Adrian Hadden/ Adam Cowen

+44 (0)20 7523 8350